A Pharmacodynamically-guided, Dose-escalation, Phase I Study to Assess the Safety of AFM11 (Recombinant Antibody Construct Against Human CD19 and CD3) in Patients With Relapsed and/or Refractory CD19 Positive B-cell NHL.

Trial Profile

A Pharmacodynamically-guided, Dose-escalation, Phase I Study to Assess the Safety of AFM11 (Recombinant Antibody Construct Against Human CD19 and CD3) in Patients With Relapsed and/or Refractory CD19 Positive B-cell NHL.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 01 Aug 2017

At a glance

  • Drugs AFM 11 (Primary)
  • Indications Non-Hodgkin's lymphoma
  • Focus Adverse reactions
  • Sponsors Affimed Therapeutics
  • Most Recent Events

    • 01 Aug 2017 According to an Affimed Therapeutics media release, this trial is nowrecruiting patients into the third dose cohort under the revised study design.
    • 01 Aug 2017 According to an Affimed Therapeutics media release, this trial has been amended in May 2016 to increase the number of trial site.
    • 18 Dec 2016 Planned End Date changed from 1 Nov 2016 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top